TENX

Tenax Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website enaxthera.com
Employees(FY) 7
ISIN US88032L6056

Performance

-0.59%

1W

-1.69%

1M

-14.48%

3M

-89.44%

6M

-83.84%

YTD

-84.76%

1Y

Profile

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Advanced Technical Analysis

Technical Analysis of TENX 2024-05-10

Overview:

In analyzing the technical indicators for TENX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for potential in...

See more ...

Recent News & Updates

2024-05-14 01:53
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-13 20:10
Tenax Therapeutics: Q1 Earnings Snapshot(Yahoo Finance)
2024-05-13 20:00
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update(Globenewswire)
2024-04-29 19:30
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)(Globenewswire)
2024-04-08 20:30
Tenax Therapeutics to Host KOL Event: LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study(Globenewswire)
2024-03-28 09:54
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-03-27 20:30
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results(Globenewswire)
2024-03-11 20:30
Tenax Therapeutics to Present at the 36th Annual Roth Conference(Globenewswire)
2024-02-28 20:00
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024(Globenewswire)
2024-02-19 19:30
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan(Globenewswire)
2024-02-07 19:53
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?(Investorplace)
2024-02-07 19:16
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering(Globenewswire)
2024-02-07 07:01
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)(Globenewswire)
2024-02-05 19:30
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)(Globenewswire)
2023-12-28 19:30
Tenax Therapeutics Announces Reverse Stock Split(Globenewswire)
2023-11-16 19:30
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board(Globenewswire)
2023-11-13 16:05
Tenax Therapeutics: Q3 Earnings Snapshot(Yahoo Finance)
2023-11-13 02:22
Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?(Investorplace)
2023-11-12 19:30
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023(Globenewswire)
2023-08-27 20:20
TENX: Second Quarter Results(Yahoo Finance)
2023-08-24 19:20
7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole(Yahoo Finance)
2023-07-18 20:30
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)(Yahoo Finance)
2023-06-22 18:24
TENX: Notice of Allowance Increases Confidence(Yahoo Finance)
2023-05-30 20:54
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)(Yahoo Finance)
2023-05-21 18:44
TENX: Prioritizing Levosimendan(Yahoo Finance)
2023-04-21 03:59
10 Stocks Targeted By Short Sellers Recently(Yahoo Finance)
2023-04-12 02:50
Tenax Therapeutics Prioritizes Development Of TNX-103 For Heart Failure(Yahoo Finance)
2023-04-11 20:45
Tenax Therapeutics Provides 2023 Business Update(Yahoo Finance)
2023-04-04 17:49
TENX: Patents Guide the Way(Yahoo Finance)
2023-03-21 20:45
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)(Yahoo Finance)

Page 1 of 4

previousnext